136759-35-8 Usage
Uses
Used in Pharmaceutical Industry:
(R)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure and chirality contribute to the development of new drugs with improved efficacy and selectivity.
Used in Organic Chemistry:
In the field of organic chemistry, (R)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid serves as an important intermediate for the synthesis of complex organic compounds. Its methoxy group allows for further functionalization and modification, leading to a wide range of applications in chemical research and development.
Used in Drug Development:
(R)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is used as a precursor in the development of novel bioactive molecules. Its structural features and chirality make it a promising candidate for the creation of new drugs with potential therapeutic applications.
Used in Chemical Research:
As a chiral molecule with a specific spatial orientation, (R)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is utilized in chemical research to study the effects of stereochemistry on the properties and reactivity of molecules. This knowledge can be applied to the design and synthesis of more effective and selective drugs and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 136759-35-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,6,7,5 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 136759-35:
(8*1)+(7*3)+(6*6)+(5*7)+(4*5)+(3*9)+(2*3)+(1*5)=158
158 % 10 = 8
So 136759-35-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H14O3/c1-15-11-5-4-8-6-10(12(13)14)3-2-9(8)7-11/h4-5,7,10H,2-3,6H2,1H3,(H,13,14)/t10-/m1/s1
136759-35-8Relevant academic research and scientific papers
Tiefenbacher, Konrad,Tr?ndlin, Lars,Mulzer, Johann,Pfaltz, Andreas
, p. 6508 - 6513 (2010)
A short enantioselective and protecting group free access to the novel antibiotic platensimycin is reported. The crucial stereogenic information is provided by iridium catalyzed asymmetric hydrogenation.
OXOPYRROLIDINE UREA FPR2 AGONISTS
-
Page/Page column 59, (2022/02/28)
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. (I)
Kappa opioid receptor ligands
-
Page/Page column 6-7, (2008/06/13)
Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid
